#### The Promise of AI for Personalized Medicine based on Medical Images

# Les promesses de l'IA pour une médecine personnalisée basée sur les images médicales

# Tal Arbel, PhD

**Professor, McGill University** 

Canada CIFAR AI Chair, Mila


**Department of Electrical and Computer Engineering** 

**Director Probabilistic Vision Group, Medical Imaging Lab** 

**Centre for Intelligent Machines** 









ila

Machine Learning



Machine Learning




#### **Computer Vision**





Machine Learning




#### **Computer Vision**






#### Medical Image Analysis



Machine Learning




#### **Computer Vision**





Medical Image Analysis




**Real clinical applications**: AI medical image analysis tools developed in my lab used in analysis of clinical trials for <u>almost all</u> new treatments for multiple sclerosis


#### **Clinical Scenario - Current Practice**








• Variety of treatments available for this patient's illness




- Variety of treatments available for this patient's illness
- Treatment decision based on efficacy:
  - Average treatment efficacy across population, choose highest

#### **Clinical Scenario – Personalized Medicine**




- Clinical and demographic information available
- **Treatment decision:** Average treatment efficacy conditioned on sub-group statistics

# The Promise of AI for Image-Based Personalized Medicine




- Integrate clinical, demographic and medical images into AI system
- Provide clinicians with an <u>AI tool</u> which predicts future individual treatment response on several treatments using <u>discovered image features</u>

# The Promise of AI for Image-Based Personalized Medicine




# The Promise of AI for Image-Based Personalized Medicine




12

#### **Deep Learning for Medical Image Analysis**




Medical imaging applications where deep learning models have achieved the SOTA Mammographic mass classification Segmentation of lesions in the brain Breast cancer metastases detection

#### **Deep Learning for Medical Image Analysis**



Medical imaging applications where deep learning models have achieved the SOTA Mammographic mass classification Segmentation of lesions in the brain Breast cancer metastases detection

#### **Deep Learning for Medical Image Analysis**



Medical imaging applications where deep learning models have achieved the SOTA Mammographic mass classification Segmentation of lesions in the brain Breast cancer metastases detection

Why haven't they been widely integrated into clinical workflow?

https://www.sciencedirect.com/science/article/pii/S1361841517301135

Very large medical images but ... Lack of relevant training data

#### Very large medical images but ... Lack of relevant training data

 Not <u>robust/generalizable</u> to real patient/data/label variability

	•	•	•	·	•	•	•	•	•	•	•
ARTIFICIAL INTELLIGENCE											
		-	•	•				•		•	
Hundreds of Al tools have been b		П	t	t	0	C	X		C	h	1
Hundreds of AI tools have been k	)Ų	II.	ţ	ţ	0	C	)2	at	C	h	):
Rundreds of Al tools have been to covid. None of them helped.	)Ų	<b> </b>	ţ	t	0	C	); ;	at	C	ĥ	): :

https://www.technologyreview.com/2021/07/30/1030329/machine-learning-ai-failed-covid-hospital-diagnosis-pandemic/

Very large medical images but ... Lack of relevant training data

- Not <u>robust/generalizable</u> to real patient/data/label variability
- DL for medical imaging make (potentially deadly) <u>mistakes</u>.

Researchers Investigate When, How Healthcare AI Models Will Fail

https://healthitanalytics.com/news/researchers-investigate-when-how-healthcare-ai-models-will-fail

Very large medical images but ... Lack of relevant training data

- Not <u>robust/generalizable</u> to real patient/data/label variability
- DL for medical imaging make (potentially deadly) <u>mistakes</u>.

Researchers Investigate When, How Healthcare AI Models Will Fail

Need to convey uncertainty in AI predictions!

https://healthitanalytics.com/news/researchers-investigate-when-how-healthcare-ai-models-will-fail

#### Lack of Interpretability of Deep Learning Models

"A challenge to radiologists embracing AI in practice is that we don't really understand how AI arrives at a particular conclusion"



**Dr. McGinty**, Chair of the American College Radiology Board of Chancellors, *MICCAI 2018* 

#### Lack of Interpretability of Deep Learning Models

"A challenge to radiologists embracing AI in practice is that we don't really understand how AI arrives at a particular conclusion"

**Dr. McGinty**, Chair of the American College Radiology Board of Chancellors, *MICCAI 2018* 


Need to open up the black box!

#### **Deep Learning Models Can Be Biased**

#### BRIEF REPORT | APPLIED MATHEMATICS | 👌

f 🍠 in 🖾 🧕

Gender imbalance in medical imaging datasets produces biased classifiers for computer-aided diagnosis




(a) Male

(b) Female

# AI skin cancer diagnoses risk being less accurate for dark skin - study

Research finds few image databases available to develop technology contain details on ethnicity or skin type



<sup>2</sup> https://www.pnas.org/doi/10.1073/pnas.1919012117


https://www.theguardian.com/society/2021/nov/09/ai-skin-cancer-diagnoses-risk-being-less-accurate-for-dark-skin-study

#### **Deep Learning Models Can Be Biased**

BRIEF REPORT | APPLIED MATHEMATICS | 👌

f 🍠 in 🖂 🧕

Gender imbalance in medical imaging datasets produces biased classifiers for computer-aided diagnosis




(a) Male

(b) Female

# AI skin cancer diagnoses risk being less accurate for dark skin - study

Research finds few image databases available to develop technology contain details on ethnicity or skin type





<sup>3</sup> https://www.pnas.org/doi/10.1073/pnas.1919012117

https://www.theguardian.com/society/2021/nov/09/ai-skin-cancer-diagnoses-risk-being-less-accurate-for-dark-skin-study

\*First\* deep learning model for personalized prediction from patients images

<u>Trustworthiness</u> and <u>reliability</u> of deep learning models needed in clinical applications:

\*First\* deep learning model for personalized prediction from patients images

<u>Trustworthiness</u> and <u>reliability</u> of deep learning models needed in clinical applications:

Uncertainty Estimation

\**First*\* deep learning model for personalized prediction from patients images

<u>Trustworthiness</u> and <u>reliability</u> of deep learning models needed in clinical applications:

- Uncertainty Estimation
- Explainability & Discovery of predictive image markers

\*First\* deep learning model for personalized prediction from patients images

<u>Trustworthiness</u> and <u>reliability</u> of deep learning models needed in clinical applications:

- Uncertainty Estimation
- Explainability & Discovery of predictive image markers
- Improving fairness

\*First\* deep learning model for personalized prediction from patients images

<u>Trustworthiness</u> and <u>reliability</u> of deep learning models needed in clinical applications:


- Uncertainty Estimation
- Explainability & Discovery of predictive image markers
- Improving fairness

<u>**Case study</u>**: Multiple Sclerosis - Long term, complex neurological disease evolution</u>


Most common neurological disease affecting young people; Canada has highest rate per capita.

#### ATLAS OF MULTIPLE SCLEROSIS

*The 2013 map produced by the Multiple Sclerosis International Federation ranked Canada No. 1, with 291 cases per 100,000 people* 



Multi-focal brain lesions visible on MRI



https://macleans.ca/society/health/could-canada-cause-multiple-sclerosis/

**Enlarging Lesion** New Lesion **Baseline** After 2 years

Appearance of new/enlarging (NE) lesions on successive MRI scans important:

 MRI markers of new disease activity since previous scan

**Enlarging Lesion** New Lesion **Baseline** After 2 years

Appearance of new/enlarging (NE) lesions on successive MRI scans important:

- MRI markers of new disease activity since previous scan
- Treatments exist to help suppress new lesions, manage symptoms (not to stop progression)
  - Different efficacies
  - Risk profiles, etc.

**Enlarging Lesion** New Lesion **Baseline** After 2 years


Appearance of new/enlarging (NE) lesions on successive MRI scans important:

- MRI markers of new disease activity since previous scan
- Treatments exist to help suppress new lesions, manage symptoms (not to stop progression)
  - Different efficacies
  - Risk profiles, etc.

• No Cure.


#### Deep Learning for Image-Based Precision Medicine

DL model that learns data driven imaging markers predictive of future disease progression for individual patients on and off treatment




<sup>33</sup> Durso-Finley *et. al*, Conference on Medical Imaging with Deep Learning (MIDL) 2022

#### Deep Learning for Personalized Prediction of Future Outcomes on and off Treatment from Images (Part-1)



<sup>34</sup> Durso-Finley *et. al*, Conference on Medical Imaging with Deep Learning (MIDL) 2022

#### Al for Personalized Predictions of Future New Lesion Counts on and off Treatments from Images



System provides estimates of **\*all**\* treatment outcomes: **factual** and **counterfactual** (regardless of the true assignment)


NE: No proven efficacy, LE: Lesser efficacy , ME: Moderate efficacy, HE: High efficacy


Durso-Finley *et. al*, Conference on Medical Imaging with Deep Learning (MIDL) 2022

#### **Factual Model Results-Binarized Regression**

#### **Baseline 1:**

Clinical features (Age, Sex, Baseline Disability)






NE: No proven efficacy, LE: Lesser efficacy , ME: Moderate efficacy, HE: High efficacy

## **Factual Model Results-Binarized Regression**

**Baseline 2:** 

Clinical (Age, Sex, Baseline Disability) + MRI Derived Features (T2 Lesion Volume, Gad lesion count)



NE: No proven efficacy, LE: Lesser efficacy , ME: Moderate efficacy, HE: High efficacy

**Baseline** 

MRI

**Clinical Data** 

## **Factual Model Results-Binarized Regression**


#### Our Model:



NE: No proven efficacy, LE: Lesser efficacy , ME: Moderate efficacy, HE: High efficacy

## Deep Learning for Clinical Decision Support (Part 1)

#### **Factual and Counterfactual Treatment Outcome Estimates**




**NE**: No proven efficacy, **LE**: Lesser efficacy , **ME**: Moderate efficacy, **HE**: High efficacy **MEDA T2** threshold: >=3 NE lesions actionable number for DMT (therapy) escalation

Durso-Finley et. al, Conference on Medical Imaging with Deep Learning (MIDL) 2022

## Deep Learning for Clinical Decision Support (Part 2)


#### **Predicting Future Treatment Effects**



#### Causal effects of treatment on the outcome for a patient

Durso-Finley et. al, Conference on Medical Imaging with Deep Learning (MIDL) 2022

#### Estimating Future Personalized Treatment Response



NE: No proven efficacy, LE: Lesser efficacy, ME: Moderate efficacy, HE: High efficacy MEDA T2: 3 Future New T2 Lesions


Durso-Finley et. al, Conference on Medical Imaging with Deep Learning (MIDL) 2022

# Great! Are we ready for clinical deployment?

Image licensed under CC BY-SA-NC. Source: https://geekdoctor.blogspot.com/2021/08/we-need-to-open-up-ai-black-box.html?linkId=128170183


#### Trustworthy Image-Based Personalized Medicine

- Uncertainty Estimation
- Explainability
- Improving fairness




#### **Trustworthy Image-Based Personalized Medicine**

AI makes mistakes! High risk in handing over to clinician



made in form of uncertainty?

#### **Trustworthy Treatment Effect Estimation**




#### Trustworthy Image-Based Personalized Medicine

- Uncertainty Estimation
- Explainability
- Improving fairness



#### **Trustworthy Image-Based Personalized** Medicine






Patient will be a future responder to Treatment A

#### Explainable Deep Learning Models for Image Based Personalized Medicine – Opening up the black box

Future **responder** to treatment A




Where was the model looking at when it made its prediction?


What are the patient specific image markers that are predictive of future response?

#### Baseline










How would the patient's current (baseline) image change were it to have a different future disease outcome?


#### Baseline






Year 1







#### Baseline




Year 1







51 Kumar et. al, MIABID Workshop, MICCAI 2022

*Identification of Personalized Image Markers Predictive of Future Patient Outcomes* 





• Goal: CF image should maintain (i) subject fidelity, (ii) target class, (iii) realism






55






#### Trustworthy Image-Based Personalized Medicine

- Uncertainty Estimation
- Explainability
- Improving fairness




#### **Trustworthy Image-Based Personalized Medicine**


Biases in DL models across population subgroups




Mehta et. al, MIDL 2023 8 Shui et. al, NeurIPS 2022 Shui et. al, In submission.




/ 59 Mehta et. al, MIDL 2023




60 Mehta et. al, MIDL 2023



61 Mehta et. al, MIDL 2023




62 Mehta et. al, MIDL 2023



/ <sub>63</sub> Mehta et. al, MIDL 2023

## The Promise of AI for Clinical Decision Support


Provide clinicians with <u>trustworthy</u> AI tools to predict future individual treatment response on different treatments using *medical* images



64 https://www.mdpi.com/2072-6694/12/2/369

## Thank you for your attention!

#### **Probabilistic Vision Group**



#### Collaborators

Douglas L. Arnold, Montreal Neurological Institute Sotirios Tsaftaris, University of Edinburgh Nick Powlowski, Microsoft Research Yarin Gal, Oxford University

#### Sponsors



This work was made possible by Biogen, BioMS, MedDay, Novartis, Roche / Genentech, and Teva who generously provided the data








# Extra Slides

#### Reliability Curve: With Bias

Reliability Curve: Mitigated Bias




Shui et. al, In submission.

67




# **Counterfactual Synthesis**


Generator losses



f(.) : binary future lesion activity classifierG(., .): Conditioned Generative moduleD(., .): Discriminator

#### **Trustworthy Treatment Effect Estimation**





Uncertainty quantification helps provide model trustworthiness